Chronic Kidney Disease Trial, Recruiting NCT05204212 Sponsor: Prof. Dr. med. Ingo Eitel Condition: Chronic Kidney Disease
Back to Chronic Kidney Disease

Chronic Kidney Disease Trial, Recruiting

NCT05204212
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults aged 18 or older
  • People who are able to give their informed consent to participate
  • People who have been diagnosed with a type of irregular heartbeat called non-valvular atrial fibrillation (AF), whether it comes and goes, has lasted a long time, or is permanent
  • People whose AF-related stroke risk has been assessed using a standard scoring system (called CHA2DS2VASc) and received a score of 2 or higher
  • People with advanced chronic kidney disease (the most severe stage, where the kidneys are working at less than 15% of normal capacity), whether or not they are receiving dialysis

Who may not be able to join:

  • People who have a medical reason why they cannot take aspirin and/or clopidogrel (a common blood-thinning medication)
  • People who need to take blood-thinning medication long-term for a reason other than their AF — for example, because they have a mechanical heart valve
  • People who currently have a blood clot in a specific part of the heart (the left atrial appendage)
  • People who have a certain type of unstable fatty deposit in the main artery leaving the heart (confirm with trial site)
  • People who are pregnant
  • People who have not given informed consent to participate
  • People who are already taking part in another clinical trial
  • People whose life expectancy is estimated to be less than 2 years

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: +49 451 500 44501

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Prof. Dr. med. Ingo Eitel
Registry
ClinicalTrials.gov
Start date
28 March 2022
Est. completion
14 January 2026

Where this trial is recruiting

🇩🇪 Germany

Primary endpoints

"Net clinical benefit"

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov